The US District Court for the District of Delaware granted in part Teva Pharmaceuticals’ renewed motion for judgment as a matter of law (JMOL), finding that substantial evidence did not support the ...

Carvedilol could be the poster child for how to lower drug prices. Since 2007, over 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which ...

High blood pressure affects nearly 50% of all American adults, an estimated 46.7%—and new high blood pressure guidelines, released earlier this month by the American Heart Association and the American ...

Results suggest that more childhood cancer survivors may benefit from a heart-saving medication called carvedilol, even long after their cancer treatment is over LOS ANGELES--(BUSINESS ...

The Supreme Court declined to hear Teva's challenge to a $235 million award to GlaxoSmithKline in a patent dispute over generic drugs involving heart medication Coreg, according to a Reuters report.

A low-dose regimen of the blood pressure medication carvedilol demonstrated safety and efficacy in improving heart health of childhood cancer survivors, according to results of a multicenter phase 2b ...

In October 2020, as reported in a previous Cooley alert, the US Court of Appeals for the Federal Circuit reinstated a jury’s verdict that Teva infringed GSK’s patented method of using its Coreg drug ...

A new court ruling has the future use of skinny labels in question, but skinny-label generics have saved Medicare a lot of money over 5 years. Skinny labels, which carve out patent-protected ...

“This narrow, case-specific review of substantial evidence does not upset the careful balance struck by the Hatch-Waxman Act regarding section viii carve-outs.”- CAFC The U.S. Court of Appeals for the ...

The U.S. Court of Appeals for the Federal Circuit sided with a jury’s 2017 finding that Teva swayed doctors away from using GlaxoSmithKline’s drug Coreg (carvedilol) for a use of its drug that was ...